Which has stronger valuation and earnings, RKTO or AARD?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is RKTO or AARD more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media refer more to RKTO or AARD?

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.93 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RKTO or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Black Diamond Therapeutics N/A -30.18% -23.91%

Do analysts prefer ICCC or RKTO?

Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 425.87%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ICCC or RKTO?

In the previous week, ImmuCell had 2 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 5 mentions for ImmuCell and 3 mentions for Rocket One Inc. Common Stock. ImmuCell's average media sentiment score of 1.28 beat Rocket One Inc. Common Stock's score of 0.63 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RKTO or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is RKTO or BMEA more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Biomea Fusion N/A -265.37% -103.96%

Do analysts prefer TELO or RKTO?

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 425.87%. Given Rocket One Inc. Common Stock's higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, TELO or RKTO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is TELO or RKTO more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Does the media favor TELO or RKTO?

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rocket One Inc. Common Stock (RKTO) Competitors

$0.95 +0.08 (+8.66%)

As of 06/26/2026 04:00 PM Eastern

Compare

RKTO vs. AARD, BDTX, ICCC, BMEA, and TELO

Should you buy Rocket One Inc. Common Stock stock or one of its competitors? MarketBeat compares Rocket One Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket One Inc. Common Stock include Aardvark Therapeutics (AARD), Black Diamond Therapeutics (BDTX), ImmuCell (ICCC), Biomea Fusion (BMEA), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does Rocket One Inc. Common Stock compare to Aardvark Therapeutics?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Rocket One Inc. Common Stock presently has a consensus target price of $5.00, suggesting a potential upside of 425.87%. Aardvark Therapeutics has a consensus target price of $19.70, suggesting a potential upside of 311.27%. Given Rocket One Inc. Common Stock's higher probable upside, equities research analysts clearly believe Rocket One Inc. Common Stock is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.93 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket One Inc. Common Stock has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.47, indicating that its share price is 347% more volatile than the broader market.

Aardvark Therapeutics' return on equity of -61.71% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Rocket One Inc. Common Stock and Aardvark Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Rocket One Inc. Common Stock currently has a consensus target price of $5.00, indicating a potential upside of 425.87%. Black Diamond Therapeutics has a consensus target price of $10.00, indicating a potential upside of 484.80%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the broader market.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has higher revenue and earnings than Rocket One Inc. Common Stock. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Black Diamond Therapeutics	$70M	1.40	$22.37M	-$0.77	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Rocket One Inc. Common Stock on 13 of the 15 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, ImmuCell had 2 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 5 mentions for ImmuCell and 3 mentions for Rocket One Inc. Common Stock. ImmuCell's average media sentiment score of 1.28 beat Rocket One Inc. Common Stock's score of 0.63 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has higher revenue and earnings than Rocket One Inc. Common Stock. ImmuCell is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.21	-$1.04M	-$0.06	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

Rocket One Inc. Common Stock has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

ImmuCell has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 425.87%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ImmuCell beats Rocket One Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Biomea Fusion?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rocket One Inc. Common Stock has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, indicating a potential upside of 425.87%. Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 543.94%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.94 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Positive
Biomea Fusion	Positive

Rocket One Inc. Common Stock's return on equity of -165.25% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Biomea Fusion beats Rocket One Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Rocket One Inc. Common Stock and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat Rocket One Inc. Common Stock's score of 0.63 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rocket One Inc. Common Stock's return on equity of -165.25% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 425.87%. Given Rocket One Inc. Common Stock's higher probable upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

Summary

Rocket One Inc. Common Stock beats Telomir Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Get Rocket One Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RKTO vs. The Competition

Export

Metric	Rocket One Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.53M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-1.19	21.56	25.87	24.18
Price / Sales	N/A	331.32	575.83	114.29
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	2.38	8.34	10.78	6.36
Net Income	-$12.47M	$23.91M	$3.58B	$337.99M
7 Day Performance	-11.96%	3.42%	2.22%	0.10%
1 Month Performance	-30.09%	1.55%	1.12%	-0.11%
1 Year Performance	-15.86%	65.22%	34.29%	27.61%

Rocket One Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RKTO Rocket One Inc. Common Stock	2.3395 of 5 stars	$0.95 +8.7%	$5.00 +425.9%	-18.7%	$19.53M	N/A	N/A	4	Analyst Upgrade
AARD Aardvark Therapeutics	4.2617 of 5 stars	$4.25 +4.2%	$19.70 +363.5%	-65.4%	$92.74M	N/A	N/A	18
BDTX Black Diamond Therapeutics	4.1185 of 5 stars	$1.61 flat	$10.00 +521.1%	-30.5%	$92.25M	$70M	N/A	90	News Coverage Positive News
ICCC ImmuCell	1.1233 of 5 stars	$9.94 +2.1%	N/A	+44.2%	$89.96M	$27.64M	N/A	70	News Coverage Analyst Upgrade Gap Down
BMEA Biomea Fusion	2.4212 of 5 stars	$1.24 +0.8%	$8.50 +585.5%	-33.7%	$89.65M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RKTO) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. AARD, BDTX, ICCC, BMEA, and TELO

How does Rocket One Inc. Common Stock compare to Aardvark Therapeutics?

Summary

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Summary

How does Rocket One Inc. Common Stock compare to ImmuCell?

Summary

How does Rocket One Inc. Common Stock compare to Biomea Fusion?

Summary

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. AARD, BDTX, ICCC, BMEA, and TELO

How does Rocket One Inc. Common Stock compare to Aardvark Therapeutics?

Which has stronger valuation and earnings, RKTO or AARD?

Do analysts rate RKTO or AARD?

Does the media refer more to RKTO or AARD?

Which has more risk and volatility, RKTO or AARD?

Is RKTO or AARD more profitable?

Do insiders and institutionals believe in RKTO or AARD?

Summary

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Do analysts rate RKTO or BDTX?

Which has more risk & volatility, RKTO or BDTX?

Does the media refer more to RKTO or BDTX?

Which has higher valuation & earnings, RKTO or BDTX?

Is RKTO or BDTX more profitable?

Do insiders and institutionals believe in RKTO or BDTX?

Summary

How does Rocket One Inc. Common Stock compare to ImmuCell?

Does the media prefer ICCC or RKTO?

Which has stronger valuation & earnings, ICCC or RKTO?

Is ICCC or RKTO more profitable?

Which has more risk & volatility, ICCC or RKTO?

Do analysts prefer ICCC or RKTO?

Do institutionals & insiders believe in ICCC or RKTO?

Summary

How does Rocket One Inc. Common Stock compare to Biomea Fusion?

Do insiders and institutionals have more ownership in RKTO or BMEA?

Which has more risk & volatility, RKTO or BMEA?

Do analysts recommend RKTO or BMEA?

Does the media favor RKTO or BMEA?

Is RKTO or BMEA more profitable?

Which has preferable earnings and valuation, RKTO or BMEA?

Summary

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Does the media favor TELO or RKTO?

Do insiders & institutionals believe in TELO or RKTO?

Is TELO or RKTO more profitable?

Do analysts prefer TELO or RKTO?

Which has more risk & volatility, TELO or RKTO?

Which has preferable earnings & valuation, TELO or RKTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools